{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-120360","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.105669+00:00","generated_at":"2026-05-16T13:33:06.984765+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cadrenal Therapeutics acquires VLX-1005, a Phase 2 12-LOX inhibitor for HIT, from Veralox","bullets":["Acquisition closed Dec 10, 2025; upfront cash $200K plus milestone payments up to $15M and 5% royalties on net sales.","VLX-1005 is a first-in-class, potent 12-LOX inhibitor with FDA Orphan Drug and Fast Track designations for HIT.","Phase 2 interim results demonstrated encouraging reductions in thromboembolic events; no deaths or serious AEs in Phase 1.","HIT affects ~56,000 confirmed diagnoses annually in the U.S.; current therapies do not address immune-driven pathogenesis.","Deal adds VLX-1005 to Cadrenal's anticoagulation pipeline alongside tecarfarin and frunexian, targeting $3B+ peak revenue potential."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-120360","json":"https://secwatch.observer/filing/0001213900-25-120360.json","markdown":"https://secwatch.observer/filing/0001213900-25-120360.md","text":"https://secwatch.observer/filing/0001213900-25-120360.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025120360/0001213900-25-120360-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390025120360/ea0269180-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:33:06.984765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}